Abstract Ki67 immunohistochemistry (IHC), commonly used as a proliferation marker in
breast cancer, has limited value for treatment decisions due to questionable analytical …

Histologic grading has been a simple and inexpensive method to assess tumor behavior
and prognosis of invasive breast cancer grading, thereby identifying patients at risk for …

As a cell proliferation biomarker, Ki-67 is principally used in ER+/HER2− breast cancer.
However, the importance and the best cutoff point of Ki-67 in triple-negative breast cancer …

Clinical success of immunotherapy is driving the need for new prognostic and predictive
assays to inform patient selection and stratification. This requirement can be met by a …

Simple Summary Despite the increased use of neoadjuvant chemotherapy in the early
setting of breast cancer, there is a clinical need for predictive markers of response in daily …

Aims The nuclear proliferation marker Ki67 assayed by immunohistochemistry has multiple
potential uses in breast cancer, but an unacceptable level of interlaboratory variability has …

Background Accurate classification of breast cancer using gene expression profiles has
contributed to a better understanding of the biological mechanisms behind the disease and …

Artificial intelligence (AI) solutions that automatically extract information from digital histology
images have shown great promise for improving pathological diagnosis. Prior to routine use …

The combined clinical and molecular heterogeneity of prostate cancer necessitates the use
of prognostic, predictive, and diagnostic biomarkers to assist the clinician with treatment …

Pathological examination is the optimal approach for diagnosing cancer, and with the
advancement of digital imaging technologies, it has spurred the emergence of …